HOW WELL DO WE REALLY UNDERSTAND COAGULATION?
In the 1960s two groups proposed a model of coagulation composed of a sequential series of steps in which activation of one clotting factor led to the activation of another, finally leading to a burst of thrombin generation 1) 2) . Each clotting factor was thought to exist as a proenzyme that could be converted to an active enzyme.
The original cascade models were subsequently modified to include the observation that some procoagulants were cofactors and did not possess enzymatic activity. In addition the clotting sequences were divided into so called extrinsic and intrinsic systems and eventually evolved into the scheme shown in Figure 1 . As can be seen, the extrinsic system consisted of factor VIIa and tissue factor, the latter being viewed as extrinsic to the circulating blood. The factors in the so called intrinsic system were all viewed as being intravascular. Both pathways could activate factor X, which, in complex with its cofactor Key observations made by several groups have led to a revision of earlier models of coagulation.
A major observation was that a complex of factor VIIa/TF activated not only factor X but also factor IX 3) . Other important observations led to the conclusion that the major initiating event in hemostasis in vivo was the formation of a factor . However, in spite of these advances, it was not clear why an intact extrinsic pathway could not compensate for the lack of factor IX or VIII in hemophilia.
CAN AN EMPHASIS ON THE ROLE OF CELLS IMPROVE OUR UNDERSTANDING OF COAGULATION?
It was recognized from the earliest studies of 
Initiation and Amplification of Coagulation The Role of the TF bearing Cell
The goal of hemostasis it to produce a platelet and fibrin plug to seal a site of injury in the blood vessel wall. This process is of hemostasis is initiated when TF bearing cells are exposed to blood at a site of injury.
TF is a transmembrane protein that acts as a receptor and cofactor for factor VII. Once bound to TF, zymogen factor VII is rapidly .
Once platelets are activated, the cofactors Va and VIIIa are rapidly localized on the platelet surface 16) . As noted above, the factor IXa formed by the factor VIIa/TF complex can diffuse through the fluid phase and also bind to the surface of activated platelets. Likewise, factor XI also binds to platelet surfaces and is activated by the "priming" amount of thrombin 12) 17) , bypassing the need for factor XIIa. The platelet bound factor XIa can activate more factor IX to IXa. The specific receptors on activated platelets that bind factor IXa also promote formation of active factor IXa/VIIIa (tenase) complexes 18) 19) . Once the platelet "tenase" complex is assembled, factor X from the plasma is activated to factor Xa on the platelet surface. Factor Xa then associates with factor Va to generate a burst of thrombin sufficient to clot fibrinogen and stabilize the initial platelet plug in a fibrin meshwork (as illustrated in figure   6 ). Factor XIII, activated by thrombin, crosslinks fibrin and further stabilizes the hemostatic plug.
Thrombin also activates TAFI, which helps to prevent lysis of the fibrin clot 20) . ).
Plasma protease inhibitors are critical in keeping the coagulation reactions confined to specific cell surfaces by inhibiting proteases that escape into the fluid phase. They also impose a threshold effect on the coagulation process 22) .
Fibrinogen Fibrinogen IIa IIa
FXIIIa TAFI Thus, in the presence of inhibitors, coagulation does not proceed unless procoagulant factors are generated in sufficient amounts to overcome the effects of inhibitors.
The role of factor XI in hemostasis has been a point of some controversy, since even severe factor XI deficiency does not result in a hemorrhagic tendency as severe as that seen in severe factor VIII or IX deficiency. This observation can be explained if factor XI is viewed as an "enhancer" or "booster" of platelet thrombin generation. In factor VIII and IX deficiency, the individual has a markedly decreased ability to generate factor Xa on the platelet surface.
Thus, patients with a severe deficiency of either factor VIII or factor IX have little or no platelet surface tenase activity, and hence platelet surface thrombin production is also markedly reduced. In contrast, patients with factor XI deficiency would always possess some platelet surface tenase activity. Such patients only lack the ability to "boost" platelet surface factor X activation by producing extra factor IXa.
Our knowledge of the platelet contribution to thrombin generation continues to evolve.
There is evidence that there is more than one The protease inhibitors AT and TFPI are present bound to heparan sulfates on the endothelial surface where they can inactivate proteases that reach the endothelial cell 27) .
REMOVAL OF THE HEMOSTATIC CLOT FIBRINOLYSIS
Even as the fibrin clot is being formed in the body, the fibrinolytic system is being initiated to 
Consumption of Coagulation Components
We normally think of disseminated intravascular coagulation (DIC) when we talk of consumption.
However, clotting factors and platelets can also be consumed during appropriate physiological attempts at hemostasis. In this case it is appropriate to replace the depleted factors with transfusion therapy. DIC can be much more complicated to manage 31) . The mainstay of treatment is to treat the underlying disorder, such as sepsis. In early or mild/compensated DIC administration of low dose heparin may be considered to control the procoagulant response to inflammation, infection or malignancy. However, in more severe or advanced DIC replacement therapy may be necessary to treat the bleeding tendency associated with depletion of coagulation factors and platelets.
Excessive fibrinolysis
The process of fibrinolysis is initiated whenever Thus, acidosis should be considered as a potential contributor to coagulopathic bleeding in medical and surgical patients.
WHAT HAPPENS AFTER THE BLEEDING STOPS?
Once hemostasis is established the process of 
DOES HEMOSTASIS INFLUENCE SUBSEQUENT WOUND HEALING?
We selected a skin punch biopsy model of wound healing 35) to test our hypoethesis in hemophilia B mice 36) . We reasoned that excessive any data on the mechanism. We hope that our experiments will lead to a better understanding of the mechanisms of wound healing and allow us to design treatment regimens that not only provide hemostasis in hemophiliac patients, but also minimize complications and normalize wound healing.
